
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity Inc. has experienced significant growth, with its point-of-care (POC) and formulary offerings expanding by more than 100% during the recent buying season, indicating strong demand for its services among U.S. medical professionals. Following a positive shift in market sentiment, the company’s shares have risen by 3.2% since September 8, reflecting investor confidence in its forthcoming performance. Furthermore, the second-quarter guidance appears not only achievable but also potentially optimistic, aided by greater visibility from increased upfront buying related to its expanded offerings.
Bears say
The current economic uncertainty has prompted downward guidance revisions for Doximity's pharmaceutical clients, negatively impacting expectations for FY'23 and FY'24. Additionally, Doximity's stock appears expensive when compared to its software peers, raising concerns about potential volatility if the company fails to meet elevated investor expectations. The anticipated scrutiny on financial performance further complicates the outlook, as any failure to deliver positive results or raise guidance could lead to significant disappointment among investors.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares